

Osteoporosis and Osteopenia Prevention: PBL

Robin Cornell Creamer, DO, FAAFP
Nathan Falk, MD, FAAFP
Justin Talbott, PT, ATC, LAT

FMX

ACTIVITY DISCLAIMER

The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

FMX

DISCLOSURE

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.

All individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.

The content of the material/presentation in this CME activity will include discussion of unapproved or investigational uses of products or devices as indicated: abaloparatide (Phase III); odanacatone (Phase III); romosozumab (Phase III)

FMX

Robin Cornell Creamer, DO, FAAFP

Assistant Director, Florida Hospital Family Medicine Residency, Winter Park; Assistant Director, Geriatric Medicine Fellowship Program, Florida Hospital, Orlando; Associate Professor, Florida State University College of Medicine, Tallahassee; Assistant Professor, University of Central Florida College of Medicine, Orlando.

Dr. Creamer is a graduate of the Chicago College of Osteopathic Medicine, Downers Grove, Illinois, and completed her family medicine residency at Florida Hospital in Orlando. She also recently completed a fellowship in geriatric medicine at Winter Park Memorial Hospital, Florida. Dr. Creamer has been practicing and teaching family medicine for more than 20 years. Following her passion for osteoporosis prevention, she leads a National Osteoporosis Foundation (NOF) support group called Central Florida Healthy Bones and has earned her NOF fracture liaison service certificate. She believes one of family medicine's critical challenges is to motivate patients to be as physically active as possible.

FMX

Nathan Falk, MD, FAAFP

Assistant Director, Sports and Family Medicine Faculty, Florida Hospital Family Medicine Residency, Winter Park, Florida.

Dr. Falk is a graduate of the University of Nebraska College of Medicine. He completed his family medicine residency at Offutt Air Force Base (AFB). He served as residency faculty and director of sports medicine at Offutt AFB/University of Nebraska where he was the 2012 Faculty of the Year. Dr. Falk specializes in advanced non-surgical care for musculoskeletal conditions, including evaluation, ultrasound, and injections, as well as medical care of the athlete, ranging from asthma to concussions. Additionally, he has interest in faculty development and teaching residents to teach. He has published numerous chapters, books, and articles on sports and family medicine topics, as well as serving as an expert lecturer from Florida to China.

FMX

Justin Talbott, PT, ATC, LAT

Physical Therapist, Florida Hospital Sports Medicine and Rehabilitation, Altamonte Springs, Florida.

Talbott is a graduate of the University of Central Florida in Orlando. He is a physical therapist and has spent just under 10 years managing Florida Hospital Sports Medicine and Rehabilitation clinics in Altamonte Springs and Winter Park. He is responsible for managing clinic operations, which includes center and therapist productivity, operating budget, employee and patient satisfaction, as well as campus and system initiatives. Talbott is a certified and licensed athletic trainer. He has presented on a topics related to lumbar, thoracic, and cervical spine; posture; osteoporosis; and other orthopedic conditions.


FMX

Learning Objectives

1. Practice applying new knowledge and competencies gained from osteoporosis and osteopenia prevention sessions, and receive feedback from expert faculty.
2. Interact collaboratively with peers to solve complex and challenging case-study scenarios.
3. Develop problem-solving skills that promote effective reasoning to manage osteoporosis and osteopenia prevention within the context of professional practice.

FMX

Audience Engagement System



FMX

Problem Based Learning Outline

- Review osteoporosis educational resources for prevention and treatment of osteoporosis
- Apply the WHO FRAX fracture risk tool for screening and treatment
- Review evaluation for secondary causes
- Practice posture and exercise recommendations
- Discuss barriers to prescribing osteoporosis medications

FMX

Educational Resources

- National Osteoporosis Foundation (NOF) Professional Learning Center- Bone Source <https://www.cme.nof.org/Resources.aspx>
 - NOF Clinicians Guidelines www.nof.org or APP
 - FRAX: <http://www.shef.ac.uk/FRAX>
 - National Institute of Health (NIH); <http://www.niams.nih.gov>
 - Mayo Clinic Shared Decision Making National Resource Center <https://osteoporosisdecisionaid.mayoclinic.org/>
 - University New Mexico. Telementoring Bone Health TeleECHO Clinic. <http://www.ofnm.org/project-echo>
- AAFP <http://familydoctor.org>

FMX

Case #1

- 65 yo Hispanic female presents for well visit. She is very health conscious, only medical concerns:
 - Mild depression (SSRI) and GERD (PPI).
- Exercises daily: pilates or spinning
- No tobacco exposure; 1 glass wine/ week
- Dietary calcium adequate (yogurt, kale, almond milk)
- Neither parent had a hip fracture
- Vitals: stable; 132 #; 5'5" (no height loss) BMI 22

FMX

Case #1-Screening DXA results

- T score Lumbar Spine (LS) -2.1
- T score Femoral Neck (FN) -2.2
- T score Total Hip (TH) -1.9

FMX

Too Fit To Fracture Recommendations

For preventing bone loss and falls, recommend a combination of:

- Strength training for major muscle groups $\geq 2x/week$
- Balance challenges daily
- Moderate-to-vigorous aerobic physical activity ≥ 150 min/week, or 20-30min per day

To reduce spine loads, recommend:

- Exercises for back extensor muscles daily
- Spine sparing strategies – hip hinge for bending, step-to-turn instead of twisting, holding loads close to body

Giangregorio LM, et al Osteoporos Int. 2014

FMX


Practice:

Exercises for Spine Safety and Bone Health

- Posture
- Impact
- Muscle strengthening


FMX

Safe Movement for Spinal Protection



FMX

Spinal Extension Exercises



National Osteoporosis Foundation

Case #2

- 67 yo white female, treated in the ED last week for a fall. She tripped over her dog.
- Her arm is in a cast due to a distal radius Colles' fracture
- She would like to have sutures removed from the laceration on her hand.

FMX

Case #2

- Only medical concern is allergic rhinitis(Flonase)
- Lactose intolerant with very little dietary calcium
- Describes herself as "not an exerciser"
- Has never smoked; alcohol < 3 drinks per day.
- Mother had a hip fracture
- Vitals: stable; 152 #; 5'3"(max Ht 5'4") BMI 26.9
- Laceration healing well; cast intact
- Fall evaluation including gait and balance is normal

FMX

Case #2 - DXA Results

- Lumbar Spine (LS) -2.5
- Femoral Neck (FN) -1.9
- Total Hip (TH) -2.1
- Diagnose osteoporosis by spine BMD and consider treatment
- Calculate FRAX for further data

FMX

Case #2 Personal and Parent Fractures

Please answer the questions below to calculate the ten year probability of fracture with BMD.

Country: US (Caucasian) Name/ID: FMX colles About the risk factor

Questionnaire:

1. Age (between 40 and 90 years) or Date of Birth: 57 M
 2. Sex: Male
 3. Weight (kg): 68.95
 4. Height (cm): 160
 5. Previous Fracture: No
 6. Parent Fractured Hip: No
 7. Current Smoking: No
 8. Glucocorticoids: No
 9. Rheumatoid arthritis: No

10. Secondary osteoporosis: No
 11. Alcohol 3 or more units/day: No
 12. Femoral neck BMD (g/cm³): -1.9
 T-Score: -1.9

Weight Conversion: 152 Pounds to kg
 Height Conversion: 63 Inches to cm

BMD: -26.9 (24-month probability of fracture 29%)
 Major osteoporosis: 29%
 Hip Fracture: 3.8%

04678919 Individuals with fracture risk assessment since 1st June 2011
www.shef.ac.uk/FRAX
 Used with Permission from International Osteoporosis Foundation

FMX

Case #2 Pharmacotherapy Advised

- T score LS -2.5; FN -1.9; TH -2.1
- FRAX Major 29%; Hip 3.8%
- Labs:
 - CMP(CrCl 45), CBC,TSH normal
 - 25(OH)D deficient 18, pt eager to take replenishment
- No contraindications to bisphosphonates
- You recommend an oral bisphosphonate.
 - Alendronate or risedronate
 - generic, evidence to reduce all fractures

FMX

AES Question #2: Barriers to Care: Patient Concerns and Compliance with Medications

Patient states she doesn't want to take any medication for her osteoporosis as she heard they might cause her jaw to rot and her bones to break. You could say okay and move on to your full morning of patients or.....

How do you discuss risks of medications?
 What Shared Decision Aid Tools do you use?


FMX

Mayo Shared Decision Aid <https://osteoporosisdecisionaid.mayoclinic.org>



Used with permission from Victor Montori, M.D., Mayo Clinic

Mayo Shared Decision Aid <https://osteoporosisdecisionaid.mayoclinic.org>



Used with permission from Victor Montori, M.D., Mayo Clinic

Case #3: Drug Holiday

78 yo white female with COPD prior smoker, was diagnosed with osteoporosis 5 yrs ago with the following:

- Height 62.5" (lifetime loss 2.5"). Wt 110 pounds.
- Vertebral Compression Fracture (VCF) T10
- DXA T-scores: LS -3.5; FN -3.2; TH -3.1; FRAX major 28% / Hip 11%

Currently after 5 yrs treatment with alendronate:

- She has been compliant with medication, no side effects or thigh pain. Labs CMP, CBC, TSH normal, CrCl 38.
- Interval height loss 0.5". Ht. 5'2", Wt. 110 pounds
- Vertebral Fracture Assessment (VFA): VCFs T10, T11
- DXA T-scores: LS -3.1; FN -2.8; TH -2.7; FRAX major 26% / Hip 9.9%

FMX

AES Question #3: Barrier to Care: Unanswered Questions- Long Term Use of Anti-resorptives and Sequential Use of Medications

Discuss options at this point?

- Continue bisphosphonate (BP)
- Drug holiday off BP
- Switch to denosumab
- Switch to teriparatide

FMX

Which Patients Benefit > 5 years of Alendronate Treatment?

- FLEX alendronate extended 5 →10 yrs. Continued prevention of spine fractures, but no effect on non-spine fracture risk.
- Hip BMD and vertebral imaging are predictive of future fractures.
- Bone turnover markers--not predictive
- Patients who may benefit from continued therapy:
 - Older with low hip BMD and/or vertebral fractures
 - Spinal fracture and femoral neck T score < -2.0
 - Femoral Neck T score ≤ -2.5

Black DM, et al.
NEJM 2012; 366:2051-2053

FMX

Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

- After 5 yr of oral bisphosphonates (BP) or 3 yr of intravenous BP, reassessment of risk should be considered.
- In women at high risk (eg, older women, low hip T-score or high FRAX, those with previous major osteoporotic fracture, or those who fracture on therapy), continuation of treatment for up to 10 yr (oral) or 6 yr (IV), with periodic evaluation, should be considered.
- The risk of atypical femoral fracture, but not ONJ, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients.
- For women not at high fracture risk after 3-5 yr of BP treatment, a drug holiday of 2-3 yr can be considered.

Adler RA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35

FMX

Case #3 Long Term use of Medications

- No uniform recommendation regarding duration, decisions need to be individualized
- Re-evaluate annually. DXA in 2 years. Consider bone turnover markers, CTX, NTX
- Consider restarting anti-resorptive or anabolic agent if risk increasing in 1-2 years
- Denosumab is a stronger anti-resorptive than BP
- Teriparatide- maintain bone growth at end of treatment with alternative agent

FMX

Key Points

- Access osteoporosis educational resources for prevention and treatment of osteoporosis.
- Apply the WHO FRAX fracture risk tool for screening and treatment
- Evaluate for risk factors and secondary causes
- Provide posture and exercise recommendations
- Use Shared Decision Aids Tools
- Long Term Medication decisions are individualized.

FMX

Questions?

FMX

Florida Hospital
Family Medicine Residency and Geriatric Medicine Fellowship

Robin Creamer, DO, CAQGM, FAAFP

Robin.Creamer.DO@FLHOSP.org

Nate Falk, MD, CAQSM, FAAFP

Nathan.Falk.MD@FLHOSP.org

Florida Hospital Sports Medicine and Rehabilitation

Justin Talbott P.T., A.T.C., L.A.T

Justin.talbott@flhosp.org

FMX

References

- Adler RA, El-Hajj Fuleihan G, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2016 Jan;31(1):16-35.
- Giangregorio, L. M., et al. "Too Fit To Fracture: exercise recommendations for individuals with osteoporosis or osteoporotic vertebral fracture." *Osteoporosis International* 25.3 (2014): 821-835.
- Mayo Clinic Shared Decision Making National Resource Center. <http://shareddecisions.mayoclinic.org/decision-aid-information/>

FMX

References

- National Bone Health Alliance. <http://www.nbha.org/resources>
- National Committee for Quality Assurance. HEDIS & Performance Measurement. www.ncqa.org/HEDISQualityMeasurement.aspx
- National Institute of Health. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH NIAMS). Osteoporosis. http://www.niams.nih.gov/health_info/bone/osteoporosis/overview.asp
- National Osteoporosis Foundation (NOF) Professional Learning Resource. <https://www.cme.nof.org/Resources.aspx>

FMX

References

- NOF Clinicians Guide to the Prevention and Treatment of Osteoporosis. <http://link.springer.com/article/10.1007%2Fs00198-014-2794-2>
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK45513>
- Telementoring Bone Health TeleECHO Clinic. University New Mexico. <http://www.ofnm.org/project-echo>
- WHO publication - Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield 2007.

FMX

Associated Session

- Osteoporosis and Osteopenia Prevention: It's Primary

FMX

Interested in More CME on this topic?
aafp.org/fmx-sports

FMX